AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Patients With Advanced Solid Malignancies

• Status: Active, not recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of the study is to assess the safety, tolerability and pharmacokinetics of a capsule of AZD6244 in patients with advanced solid malignancies

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca

Criteria

Inclusion Criteria:

• cancer which is refractory to standard therapies

• WHO performance status 0-2

• evidence of post-menopausal status or negative pregnancy test

Exclusion Criteria:

• Radiotherapy/chemotherapy within 21 days prior to entry

• brain metastases/spinal cord compression unless stable off steroids/anticonvulsants

• evidence of severe/uncontrolled systemic disease

• participated in an investigational drug study within 30 days